Corticotropin-Releasing Factor Receptors Differentially Regulate Stress-Induced Tau Phosphorylation

Article (PDF Available)inThe Journal of Neuroscience : The Official Journal of the Society for Neuroscience 27(24):6552-62 · July 2007with10 Reads
DOI: 10.1523/JNEUROSCI.5173-06.2007 · Source: PubMed
Hyperphosphorylation of the microtubule-associated protein tau is a key event in the development of Alzheimer's disease (AD) neuropathology. Acute stress can induce hippocampal tau phosphorylation (tau-P) in rodents, but the mechanisms and pathogenic relevance of this response are unclear. Here, we find that hippocampal tau-P elicited by an acute emotional stressor, restraint, was not affected by preventing the stress-induced rise in glucocorticoids but was blocked by genetic or pharmacologic disruption of signaling through the type 1 corticotropin-releasing factor receptor (CRFR1). Conversely, these responses were exaggerated in CRFR2-deficient mice. Parallel CRFR dependence was seen in the stress-induced activation of specific tau kinases. Repeated stress exposure elicited cumulative effects on tau-P and its sequestration in an insoluble, and potentially pathogenic, form. These findings support differential regulatory roles for CRFRs in an AD-relevant form of neuronal plasticity and may link datasets documenting alterations in the CRF signaling system in AD and implicating chronic stress as a risk factor in age-related neurological disorders.
Neurobiology of Disease
Corticotropin-Releasing Factor Receptors Differentially
Regulate Stress-Induced Tau Phosphorylation
Robert A. Rissman,
Kuo-Fen Lee,
Wylie Vale,
and Paul E. Sawchenko
Laboratory of Neuronal Structure and Function and
The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies
and Foundation for Medical Research, La Jolla, California 92037
Hyperphosphorylation of the microtubule-associated protein tau is a key event in the development of Alzheimer’s disease (AD) neuro-
pathology. Acute stress can induce hippocampal tau phosphorylation (tau-P) in rodents, but the mechanisms and pathogenic relevance
of this response are unclear. Here, we find that hippocampal tau-P elicited by an acute emotional stressor, restraint, was not affected by
preventing the stress-induced rise in glucocorticoids but was blocked by genetic or pharmacologic disruption of signaling through the
type 1 corticotropin-releasing factor receptor (CRFR1). Conversely, these responses were exaggerated in CRFR2-deficient mice. Parallel
CRFR dependence was seen in the stress-induced activation of specific tau kinases. Repeated stress exposure elicited cumulative effects
on tau-P and its sequestration in an insoluble, and potentially pathogenic, form. These findings support differential regulatory roles for
CRFRs in an AD-relevant form of neuronal plasticity and may link datasets documenting alterations in the CRF signaling system in AD
and implicating chronic stress as a risk factor in age-related neurological disorders.
Key words: Alzheimer’s disease; antalarmin corticotropin-releasing factor; corticotropin-releasing hormone; hippocampus; restraint
stress; tau phosphorylation
Alzheimer’s disease (AD) is defined neuropathologically by the
accumulation of
-amyloid plaques and neurofibrillary tangles
(NFTs), the latter consisting of hyperphosphorylated forms of
the microtubule-associated protein tau. Hyperphosphorylated
tau exhibits reduced ability to bind and stabilize microtubules
and can self-aggregate to form insoluble paired helical filaments
(PHFs), which comprise NFTs (Gustke et al., 1992; Bramblett et
al., 1993; Alonso et al., 1996). The incidence of NFTs is positively
correlated with cognitive deficit and neuronal loss in AD (Arria-
gada et al., 1992; Gomez-Isla et al., 1997), and the discovery that
mutations in the tau gene underlie autosomal dominant forms of
frontotemporal dementia suggests that pathological changes in
tau can serve as a principal cause of neurodegeneration and cog-
nitive impairment (Hutton et al., 1998; Poorkaj et al., 1998; Spill-
antini et al., 1998).
Exposure to a range of environmental insults, or stresses, can
activate tau kinases and induce tau phosphorylation (tau-P) in
the rodent CNS (Korneyev et al., 1995; Papasozomenos, 1996;
Korneyev, 1998; Yanagisawa et al., 1999; Planel et al., 2001, 2004;
Arendt et al., 2003; Feng et al., 2005). This effect has been re-
ported consistently in the hippocampal formation, a key struc-
ture in learning and memory, and the initial site of tau pathology
in AD (Braak and Braak, 1991). Although acute stress-induced
tau-P is reversible, the mechanisms that govern this phenomenon
are unknown, and it is unclear whether and how it may be man-
ifest under chronic stress conditions. Addressing these questions
may better define the elusive links between the stress axis and
AD-related pathogenic processes, as increased exposure and/or
sensitivity to stress in humans and rodent models confers in-
creased risk of dementia and AD neuropathology (Wilson et al.,
2003; Jeong et al., 2006).
Warranting consideration in this respect are glucocorticoids,
dominant stress hormones whose elevated levels in aging have
been linked to increased neuronal vulnerability in hippocampus
(Sapolsky et al., 1985, 1986). However, acute stress-induced
tau-P is reportedly unaffected in adrenalectomized mice (Kor-
neyev et al., 1995), suggesting that glucocorticoid secretion may
not be pivotally involved. Alternatively, the corticotropin-
releasing factor (CRF) signaling system plays an essential role in
initiating pituitary–adrenal responses to stress and has been im-
plicated as a transmitter/modulator in CNS systems that mediate
complementary autonomic and behavioral adjustments, earning
consideration as a general mediator/integrator of stress adapta-
tions (Chadwick et al., 1993). CRF and related ligands (urocort-
ins 1–3) exert their biological effects via two G-protein-coupled
receptors [CRF receptor 1 (CRFR1) and CRFR2] that are differ-
entially distributed in brain (Van Pett et al., 2000), and exert
convergent effects on a range of stress-related endpoints (Bale
and Vale, 2004). CRFR ligands can confer neuroprotection, in
Received Nov. 29, 2006; revised May 10, 2007; accepted May 11, 2007.
This work was supported by National Institutes of Health Grant DK026741, the Clayton Medical Research Foun-
dation, and the Ellison Medical Foundation and American Federation for Aging Research (R.A.R.). K.-F.L., W.V., and
P.E.S. are senior investigators of the Clayton Medical Research Foundation. We thank Drs. J. Serrats, D. Brown, Z. F.
Yuan, and J. Radley for helpful discussions and K. Trulock and C. Arias for technical assistance. We also thank Dr. G.
Chrousos for providing antalarmin, Dr. R. Valentino for antalarmin protocols, Dr. P. Davies for the PHF-1 antibody,
and Dr. G. Drewes for permission to reproduce portions of his graphic incorporated in Figure 8.
Correspondence should be addressed to either Robert A. Rissman or Paul E. Sawchenko, Laboratory of Neuronal
Structure and Function, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037,
E-mail: or
Copyright © 2007 Society for Neuroscience 0270-6474/07/276552-11$15.00/0
6552 The Journal of Neuroscience, June 13, 2007 27(24):6552– 6562
vitro, by altering amyloid precursor protein processing and sup-
pressing tau kinases, and reduced central CRF expression has
been documented early in AD progression (Rehman, 2002;
Bayatti and Behl, 2005). Nevertheless, the nature of any associa-
tion between the CRF system and AD-related pathogenesis re-
mains to be elucidated. Here, we provide evidence to support a
push–pull involvement of CRFRs in regulating stress-induced
tau-P and tau kinase activity in murine hippocampus.
Materials and Methods
CRFR knock-out mice. Mutant mice and littermate wild-type (wt) con-
trols were bred from heterozygote breeder pairs of established lines back-
crossed to founder mice to achieve a pure C57BL/6 background (Smith et
al., 1998; Bale et al., 2000). Genotype was determined by PCR, and males
were used for experimentation at 15–22 weeks of age. Pregnant females
used for generating CRFR1-deficient mice received drinking water sup-
plemented with corticosterone (10
g/ml; Sigma-Aldrich, St. Louis,
MO) from embryonic day 12 to postnatal day 14 to prevent early mor-
tality as a result of pulmonary dysplasia (Smith et al., 1998). Because
mice exhibit adrenal cortical agenesis, experimental animals
were reinstated on corticosterone for 21 d before testing to allow the
normal nocturnal bias in appetitive behavior to approximate the circa-
dian fluctuation in circulating hormone levels. To assess effectiveness of
the replacement regimen, plasma corticosterone levels were determined
by RIA from blood samples collected when the mice were killed. The Salk
Institute Institutional Animal Care and Use Committee approved all
experimental protocols.
Adrenalectomy and corticosterone replacement. Twelve-week-old male
wt C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME) underwent
adrenalectomy (ADX) via bilateral incisions on the dorsolateral flanks
under isoflurane anesthesia. ADX mice received replacement corticoste-
rone (10
g/ml) in drinking water containing 0.9% saline immediately
after surgery. Animals were used in stress experiments 21 d after surgery.
Restraint stress. Acute restraint stress involved placing mice in venti-
lated 50 ml conical tubes for 30 min; repeated stress involved 14 consec-
utive daily exposures. Animals were killed at various intervals ranging
from 20 min to 24 h after stress. Control mice were handled comparably
but were not otherwise manipulated.
Intracerebroventricular injections. CRFR1
and CRFR2
along with age-matched wt controls (n 3/group), were anesthetized
with isoflurane and implanted stereotaxically with 26 ga guide cannulas
(Plastics One, Wallingford, CT) aimed to terminate above the lateral
ventricle. Cannulas were affixed to the skull with dental acrylic adhering
to jeweler’s screws partially driven into the skull and sealed with stylets.
After7dofrecovery, stylets were replaced with 33 ga injection cannulas,
and 2 h later the animals were remotely injected with 0.5
g of synthetic
mouse/human CRF in 2
l of saline, or vehicle alone, over 1 min. To
approximate the time frame used in acute stress experiments, animals
were killed 40 min after intracerebroventricular injection and perfused
for immunohistochemistry, as described below. CRF was provided by
Dr. J. Rivier (Salk Institute).
In vivo pharmacology. The small-molecule CRFR1-selective antagonist
antalarmin (Webster et al., 1996) was administered (20 mg/kg, i.p. injec-
tion) 20 min before stress exposure. All animals were handled twice daily
for 28 d before experimentation and received daily mock intraperitoneal
injections to minimize stress of injection at testing. Antalarmin was sol-
ubilized in equal volumes of absolute ethanol and Cremaphor EL
(Sigma-Aldrich), as described previously (Webster et al., 1996; Pernar et
al., 2004). This stock solution was diluted in prewarmed (50°C) distilled
water and adjusted to a final concentration of 4 mg/ml immediately
before injection.
Western blot analysis. Mice were anesthetized with sodium pentobar-
bital (40 mg/kg), which has been demonstrated to not influence tau-P
over the time frame used here (Papasozomenos, 1996). After sedation,
animals were decapitated, and the hippocampus was rapidly dissected
and frozen on dry ice. Hippocampal tissues were homogenized in radio-
immunoprecipitation assay (RIPA) buffer (50 m
M Tris-HCl, pH 7.4,
0.1% SDS, 1% NP-40, 0.25% sodium deoxycholate, 150 m
M NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM Na
, and 1
M okadaic acid). Before
homogenization, protease inhibitors PMSF, NaF (1 m
M), aprotinin, leu-
peptin, and pepstatin (1
g/ml each) were added. RIPA fractions were
obtained by centrifuging twice at 40,000 g for 20 min, and the super-
natant was collected. For analysis of tau solubility (repeated stress), se-
quential fractionation of RAB and RIPA extracts were performed as de-
scribed previously (Higuchi et al., 2002; Kraemer et al., 2003). In this
case, tissues were first homogenized in high-salt RAB (0.1
M MES, 0.75
NaCl, 1 m
M EGTA, and 0.5 mM MgSO
) and centrifuged at 40,000 g for
40 min. The supernatant was collected (soluble RAB fraction), and pellets
were resuspended in RIPA buffer to obtain detergent-soluble fractions.
Protein concentrations were determined using a BCA Protein Assay Kit
(Pierce Biotechnology, Rockford, IL). Proteins were then boiled in sam-
ple buffer containing SDS, BME, and glycerol at 95°C for 5 min. Six
micrograms of protein were then separated by 12% SDS-PAGE. Proteins
were transferred to nitrocellulose membrane (0.2
m; Bio-Rad, Her-
cules, CA) and incubated in primary antibodies diluted in 5% milk-
PBS-T overnight at 4°C. Primary antibodies were detected with either
anti-mouse or -rabbit horseradish peroxidase-linked secondary antibod-
ies (1:1000; EMD Biosciences, La Jolla, CA) and developed with an en-
hanced chemiluminescence Western blot detection kit (Supersignal
West Pico; Pierce Biotechnology). Background subtraction was per-
formed, and quantitative band intensity readings were obtained using
NIH Image software.
Antibodies. Well characterized phospho-specific antibodies were used
for detection of phosphorylated residues on mouse tau. For Western
blots, T
(1:1000; Biosource, Camarillo, CA),
(1:500; AT8; Pierce Biotechnology), and S
PHF-1; gift from Dr. P. Davies, Albert Einstein College of Medicine,
Bronx, NY). These antibodies were chosen based on their ability to re-
solve target bands at the appropriate molecular weight for phosphory-
lated tau (i.e., 50–75 kDa). Phospho-specific antibodies against S
, and S
phosphorylated tau (Biosource) were also tested but
were found to resolve only very high-molecular-weight target bands (i.e.,
100 kDa) and were therefore excluded from the analysis. Antibody
PHF-1 (1:500) was used for detection of phosphorylated tau in immu-
nohistochemical analyses. Specificity of PHF-1 in mouse tissue was con-
firmed by pretreating sections from stressed mice with alkaline phospha-
tase (40 mg/ml; Sigma-Aldrich), which eliminated detectable PHF-1
labeling in all experimental groups (data not shown). For assessment of
tau kinases, specific antibodies to phosphorylation sites or activator pro-
teins were used. This included total glycogen synthase kinase-3
; 1:2500; BD Biosciences, San Diego, CA), activated GSK-3
1:1000; BD Biosciences), inactive GSK-3
; 1:1000; Cell Signaling
Technology, Danvers, MA), cyclin-dependent kinase 5 (cdk5; 1:1000;
EMD Biosciences), cdk5 activator proteins, p25 and p35 (1:1000; Santa
Cruz Biotechnology, Santa Cruz, CA), phosphorylated c-Jun-N-terminal
kinase (JNK; 1:1000; Cell Signaling Technology), mitogen-activated pro-
tein (MAP) kinases [extracellular signal-regulated kinases 1 and 2
(ERK1/2); 1:500; Cell Signaling Technology], and the catalytic subunit of
protein phosphatase 2A (PP2A-c; 1:5000; BD Biosciences).
-Actin (1:
2000; Sigma-Aldrich) was used as a control for protein loading.
Immunohistochemistry. Mice were perfused with 4% paraformalde-
hyde as described previously (Bittencourt and Sawchenko, 2000). Thirty-
micrometer-thick frozen sections were cut on a sliding microtome and
stored at 20°C in cryoprotectant solution (20% glycerol and 30% eth-
ylene glycol in 0.1
M phosphate buffer). PHF-1 was used to detect tau-P in
free-floating sections containing hippocampus using Mouse-on-Mouse
Immunodetection Kit reagents (Vector Laboratories, Burlingame, CA)
to avoid detection of endogenous mouse Ig. Endogenous peroxidase was
quenched with 0.3% hydrogen peroxide, followed by 1% sodium boro-
hydride to reduce free aldehydes. Reaction product was developed using
a nickel-enhanced glucose oxidase method (Shu et al., 1988).
Statistical analyses. Integrated intensity readings from Western blots
were analyzed using either a one- or two-way ANOVA using Prism4
software (GraphPad, San Diego, CA). Resultant data were plotted on bar
graphs, with data expressed as mean SEM percentage of control values.
Rissman et al. CRF Receptors and Tau Phosphorylation J. Neurosci., June 13, 2007 27(24):6552– 6562 6553
Time course of tau-P after acute restraint stress
We initially determined whether increased tau-P was observable
in response to acute restraint, an acknowledged “emotional”
stressor (Sawchenko et al., 2000). Western analysis was used to
examine tau-P at several AD-relevant N- and C-terminal sites
(AT8), T
(PHF-1), and
] in hippocampal extracts from C57BL/6 mice killed at vari
ous intervals after a single 30 min episode of restraint stress.
Relative to basal (nonstressed) values, all sites exhibited signifi-
cant increases in phosphorylation that were apparent at the ter-
mination of stress (0 min), with peak elevations (2- to 10-fold)
achieved 20 40 min later and sustained through 60 min (Fig. 1).
By 90 min, levels were reduced to or near those of unstressed
controls. These results demonstrate that a representative emo-
tional stressor induces rapid and reversible increases in tau-P at
multiple AD-relevant sites. Increments in tau-P were quite stable
over 20 60 min after stress, and the 20 min time point was se-
lected for subsequent analyses.
Glucocorticoid involvement in stress-induced
tau phosphorylation?
Because of the dominant role of glucocorticoids in mediating
stress effects and their implication in neuronal loss (Sapolsky et
al., 1985, 1986) and pathology in mouse models of AD (Green et
al., 2006), we tested whether stress-induced tau-P was dependent
on stress-induced glucocorticoid secretion. Although a previous
study used immunoassay and found no effect of ADX on PHF-1
reactivity after acute cold water stress (Korneyev et al., 1995),
phosphatase inhibitors were not used, and only soluble fractions
of tau protein were examined. We examined stress-induced tau-P
responses at the AT8 and PHF-1 sites in hippocampal extracts
from ADX and control mice exposed to acute restraint stress (Fig.
2). Robust stress-induced tau-P responses were observed in ADX
mice that did not significantly differ from those of intact controls
at either the AT8 or PHF-1 phosphorylation sites (each p 0.10).
These results confirm that acute stress-induced tau-P is not de-
pendent on glucocorticoid secretion.
CRFRs differentially regulate stress-induced
tau phosphorylation
The CRF family of signaling molecules is broadly involved in
physiological and behavioral responses to stress (Chadwick et al.,
1993) and undergoes alterations early in AD progression (Davis
et al., 1999). However, the nature of its involvement in AD neu-
ropathology is unclear. We next investigated the role of CRFRs in
acute stress-induced tau phosphorylation using mice deficient in
CRFR1 (Smith et al., 1998) or CRFR2 (Bale et al., 2000). Western
analyses indicated a tendency for CRFR1
mice to exhibit
higher basal levels of tau-P than unstressed wt animals at several
sites, although this difference was statistically reliable only at the
AT8 epitope ( p 0.01) (Fig. 3). More importantly, CRFR1-
deficient mice failed to exhibit significant increases in tau-P at
any site at 20 min after stress, compared with age-matched wt
controls. In contrast, CRFR2 knock-outs displayed normal basal
levels of tau-P ( p 0.05 vs wt) but showed robust responses to
acute stress that commonly exceeded those seen in wt animals.
Specifically, phosphorylation responses of CRFR2
mice were
significantly greater than those of wt animals at the S
( p
0.01), S
( p 0.001), T
( p 0.05), T
( p 0.05), and
PHF-1 ( p 0.01) sites. Phosphorylation responses of CRFR2
null mice at the AT8 and S
sites did not differ significantly
from those of wt stressed animals ( p 0.05).
To probe the localization of tau-P responses, immunohisto-
chemical methods were used to examine the distribution of
PHF-1 reactivity and its stress and CRFR dependence. Immuno-
labeling results were highly compatible with biochemical data in
showing prominent upregulation of PHF-1 staining in wt mice in
response to stress, which was attenuated and exaggerated in
CRFR1- and CRFR2-deleted animals, respectively (Fig. 4A). In
the dentate gyrus of stressed wt animals, PHF-1 positive cell bod-
ies were seen primarily in the hilus (polymorph and subgranular
regions), but also in deep aspects of the granule cell layer. We also
Figure 1. Time course of stress-induced tau phosphorylation. Western blots of hippocampal
extracts probed for tau-P at select AD-relevant sites in unstressed controls (C) and mice killed 0,
signal under basal conditions was low but rose immediately after stress to levels that were
markedly increased (2- to 10-fold) over control levels through 60 min and diminished thereaf-
ter. The 20 min poststress time point was adopted for use in subsequent experiments.
was used as a loading control.
Figure 2. Role of glucocorticoids in stress-induced tau-P. Western blot analysis of hip-
pocampal tau-P at the AT8 and PHF-1 sites under control (C) and acute stress (S) conditions in
intactandADXmice.Quantitativeanalysis,expressedasmean SEMpercentageofintegrated
intensity values of intact unstressed controls, reveals that intact and ADX animals manifest
comparably robust stress-induced increments in tau-P at each site, whose magnitude did not
differ significantly. **Differs significantly from intact, unstressed controls ( p 0.001); ns,
nonsignificant ( p 0.05). n 3 mice per condition.
-Actin was used as a loading control.
6554 J. Neurosci., June 13, 2007 27(24):6552– 6562 Rissman et al. CRF Receptors and Tau Phosphorylation
observed PHF-1 positive mossy fibers and a band of punctate
(presumably axonal) elements in the inner third of the molecular
layer. In Ammon’s Horn, dominant features included labeled
perikarya scattered mainly throughout the pyramidal layer and
proximal dendritic zones and bands of axon terminal-like puncta
engulfing the pyramidal cell layer and in stratum lacunosum-
moleculare. Radially oriented processes, some traceable to la-
beled cell bodies and presumably representing dendritic labeling,
were seen in stressed wt and CRFR2
animals. Alterations in
immunostaining as a function of stress and genotype were man-
ifest as differences in the number and/or intensity of labeled ele-
ments, with no discernible differences in distribution.
To determine whether CRF is capable of independently elic-
iting hippocampal tau-P, wt and CRFR-deficient mice were im-
planted with lateral ventricular cannulas for intracerebroventric-
ular injection. Resultant PHF-1 immunoreactivity was examined
40 min after administration of CRF or saline vehicle (Fig. 4 B).
The general pattern of results was similar to that observed in
response to stress, in that wt and CRFR2
mice treated with
peptide displayed robust increases in hippocampal tau-P,
whereas labeling in CRFR1
animals was comparable with the
low level seen in saline-injected controls. In the dentate gyrus,
PHF-1 positive cell bodies were seen in the hilus and deep aspects
of the granule cell layer (Fig. 4 B). In Ammon’s Horn, we ob-
served PHF-1 labeling in mossy fibers and in the form of punctate
pericellular labeling throughout the pyramidal cell layer and,
more sporadically, in the dendritic zone, with particular concen-
tration at the septal pole of the hippocampus (data not shown). In
contrast to stress effects, however, we did not observe labeling of
pyramidal neurons or their processes after intracerebroventricu-
lar CRF injections. These findings indicate that central CRF ad-
ministration at least partially recapitulates the effects of stress and
demonstrates a similar dependence on CRFR integrity.
Effects of pharmacologic blockade of CRFR1
Interpretation of data derived from conventional knock-out an-
imals may be complicated by developmental or indirect effects of
lifelong lack of expression of the targeted gene. This is particularly
true of CRFR1-deficient mice, which exhibit chronically im-
paired pituitary–adrenal function (Smith et al., 1998). Despite
efforts to mitigate such effects by steroid replacement perinatally
and immediately before experimentation (see Materials and
Methods), confidence in the assertion of a regulatory role for
CRFR1 in this context would be bolstered if the effects were
maintained in the face of acute disruption of receptor function.
We therefore assessed the effect of antalarmin, a small-molecule,
selective CRFR1 antagonist (Webster et al., 1996), on basal and
stress-induced tau-P. Neither antalarmin nor the administration
vehicle significantly altered basal levels of tau-P at the AT8 or
PHF-1 sites, relative to untreated controls (Fig. 5). However, an-
talarmin treatment prevented stress-induced increments in
phosphorylation at both sites (lanes 5– 6; each p 0.10 vs un-
treated controls). Phosphorylation responses in stressed, vehicle-
treated animals were comparable with those of stressed, un-
treated controls and significantly elevated over vehicle control
levels ( p 0.01). These findings support a specific involvement
of CRFR1 signaling in stress-induced tau-P.
Modulation of tau kinase activity by stress and CRFRs
To identify potential mediators of acute stress-induced tau-P, we
used antibodies specific to active and inactive states of kinases
implicated in tau-P in the same tissue extracts used above to
interrogate changes in stress-induced kinase activation and their
Figure 3. Differential regulation of stress-induced tau-P by CRFR status. Phosphorylation
responses of seven AD-relevant tau sites in hippocampal extracts from wt, CRFR1
, and
mice killed at 20 min after acute restraint stress (S) or no treatment (C). Quantitative
analysis revealed that wt animals displayed the expected increases in tau-P after stress at all
epitopes. CRFR1
animals displayed elevated basal levels of phosphorylation at the AT8 and
PHF-1 sites but did not manifest significantly increased responses after stress at any site. Con-
versely, CRFR2
mice showed normal basal levels of tau-P at all sites but exaggerated
responses to stress at five of the seven epitopes assayed. Data are presented as mean SEM
percentageofwtcontrolvalues.*Differssignificantlyfromunstressedwtcondition( p 0.01);
**p 0.001;
differs from wt stressed group ( p 0.05). n 3 mice per condition.
was used as a loading control.
Rissman et al. CRF Receptors and Tau Phosphorylation J. Neurosci., June 13, 2007 27(24):6552– 6562 6555
CRFR dependence (Fig. 6). Several kinases examined, including
the active (phosphorylated at Y
or pY
but not the inactive
), or total (unphosphorylated) form of GSK-3
, the pT
form of the 46 and 54 kDa c-Jun N-terminal protein kinases
(JNK46/54), and the pT
form of the mitogen-activated
protein kinases, ERK2, but not ERK1, displayed upregulation in
response to acute restraint. The time courses of stress effects seen
on these kinases were similar to those shown in Figure 1 for
stress-induced tau-P (data not shown). Relative levels of cdk5
were unchanged from steady state over the poststress intervals
examined, but one of its regulatory proteins, p35, was robustly
upregulated. We were unable to reproducibly detect the p35-
truncated product, p25.
When tested in hippocampal extracts from wt and knock-out
mice, each of the stress-responsive kinase forms or regulators also
exhibited modulation as a function of CRFR status that mirrored
some or all of the effects of genotype on restraint-induced tau-P.
The activated (pY
) form of GSK-3
, implicated in phosphor
ylating tau at S
, and PHF-1 sites, was most similar in
that the stress-induced increment seen in wt mice was not evident
in CRFR1
animals and was exaggerated in CRFR2
Phosphorylation responses of both JNK isoforms were also sig-
nificantly greater in CRFR2 knock-outs than in wt controls ( p
0.05). These kinases also exhibited pronounced elevations in
basal phosphorylation in CRFR1-deficient mice, whose magni-
tude rivaled or exceeded stress-induced levels in wt mice. This
may relate to the elevated tau-P levels seen under this condition at
the AT8 and PHF-1 sites, although less-marked elevations of
phosphorylated GSK-3
and ERK2, and of p35 levels, in un-
stressed CRFR1
mice may also contribute in this regard.
Overall, these results identify several tau kinases as potential ef-
fectors of CRFR-dependent effects of acute emotional stress on
Tau phosphorylation in response to repeated stress
Because past and present data characterize acute stress-induced
tau-P as a transient phenomenon, its relevance to neuropathol-
ogy may be questioned. Data from animal models and AD brain
have demonstrated that NFTs and other manifestations of tau
pathology are dependent on aberrantly phosphorylated tau being
sequestered into insoluble cellular fractions (Iqbal et al., 1994).
We therefore used sequential fractionation in the absence (RAB
buffer; see Materials and Methods) and presence (RIPA buffer) of
detergents to compare the persistence and solubility of phos-
phorylated tau in animals subjected to acute versus repeated (14
consecutive daily exposures) restraint stress (Fig. 7). Groups of
mice in each condition were killed 20 min or 24 h after their final
or only stress episode. Results from the acute stress condition
replicated findings detailed above in showing increased phos-
phorylation at the AT8 and PHF-1 sites 20 min after stress. At
24 h after stress, relative levels of tau-P were indistinguishable
from unstressed animals (lane 3). In terms of solubility, phos-
phorylated tau induced by acute stress was detected only in the
soluble fraction; that is, no additional signal was evident after
Figure 4. Cellular localization of stress- and peptide-induced tau-P. A, Immunoperoxidase staining for PHF-1 immunoreactivity in the dentate gyrus (top) and CA1 field (bottom) of mouse
hippocampus as a function of stress status and genotype. Phosphorylation is localized to distinct perikaryal/dendritic and axonal elements (see Results) and, importantly, varies with stress exposure
and CRFR status in a manner identical to that seen by Western analysis (Fig. 3). B, PHF-1 in the dentate gyrus of mice injected intracerebroventricularly with synthetic CRF. Tau-P varied as a function
of genotype in a manner similar to that seen in stressed animals (A). gr, Granule cell layer; mol, molecular layer; pyr, pyramidal layer; slm, stratum lacunosum-moleculare; sr, stratum radiatum.
6556 J. Neurosci., June 13, 2007 27(24):6552– 6562 Rissman et al. CRF Receptors and Tau Phosphorylation
further extraction with detergent (lanes 6 8). In contrast, under
repeated stress conditions, comparably elevated AT8 and PHF-1
signal were present in soluble fractions at both 20 min and 24 h
after the final restraint episode. In addition, extraction of
detergent-soluble proteins (RIPA) revealed significant occur-
rence of phosphorylated tau at both time points (lanes 9 –10).
These results suggest that repeated stress leads to chronic eleva-
tions in phosphorylated tau and a shift in its disposition toward
more insoluble, and potentially pathogenic, forms.
Phosphatase involvement in restraint-induced
tau phosphorylation?
Alterations in tau phosphatase activity have been implicated as
contributing to stress-induced tau-P (Planel et al., 2001, 2004,
2007). To determine whether similar changes are associated with
acute or repeated restraint stress, we analyzed the same extracts
used in the preceding analysis (Fig. 7), for alterations in the cat-
alytic subunit of the dominant tau phosphatase, PP2A (PP2A-c).
We found no evidence of PP2A-c in detergent-soluble RIPA frac-
tions under any experimental condition (data not shown). In
soluble RAB fractions, relative levels of PP2A-c from hippocampi
of acute stressed mice did not differ reliably from controls (lanes
1–3) but were significantly elevated at both 20 min ( p 0.001)
and 24 h ( p 0.01; lanes 4 –5; see supplemental Fig. 1, available
at as supplemental material) after repeated
stress. Although additional characterization is needed, these find-
ings identify PP2A as a potential contributor to alterations in
tau-P under repeated stress conditions.
Our findings extend the range of insults that provoke tau-P to
include a representative emotional stressor and provide evidence
on its mechanism (Fig. 8). We fail to implicate stress-induced
glucocorticoid secretion in this phenomenon but provide data
from pharmacologic and genetic manipulation to support a dif-
ferential involvement of CRFRs. The abrogation of stress-
induced tau-P in CRFR1-deficient animals and the enhancement
observed in CRFR2 mutants were paralleled by altered activities
of specific tau kinases. Furthermore, the demonstration that re-
peated stress exerts cumulative increases in tau-P and results in its
sequestration in insoluble forms defines a possible underpinning
for evidence implicating chronic stress as a risk factor in age-
related neurological disorders, including AD.
Relationship to previous studies
Tau normally binds and stabilizes neuronal microtubules, facili-
tating their roles in cellular structure, polarity, and transport
(Stamer et al., 2002). Phosphorylation can disrupt these activities
and promote cytoskeletal destabilization (Sengupta et al., 1998).
Aberrantly phosphorylated forms of tau aggregate into PHFs, and
these aggregate into insoluble NFTs, a defining feature of AD
(Kopke et al., 1993). In this light, the observation that acute stress
results in tau-P at AD-relevant sites defines one potential means
by which stress exposure may translate into neuropathology. This
effect has been elicited by a range of strenuous challenges, includ-
ing heat shock (Papasozomenos, 1996), starvation (Yanagisawa
et al., 1999; Planel et al., 2001), forced swimming in cold water
(Korneyev et al., 1995; Okawa et al., 2003; Feng et al., 2005; Yo-
shida et al., 2006), glucoprivation (Planel et al., 2004), ether in-
halation (Ikeda et al., 2007), and hibernation (Arendt et al., 2003;
Hartig et al., 2007). Two broad categories of stress models are
now commonly recognized. These may be termed “physiologi-
cal” and “emotional” and are distinguished by the sensory mo-
dalities that register the challenges, the patterns of neuronal acti-
vation they induce in brain, the extent to which they invoke
affective responses, and the circuitry that mediates adaptive re-
sponses to them (Sawchenko et al., 1996; Watts, 1996; Herman
and Cullinan, 1997; Dayas et al., 2001). Whereas the stressors
shown previously to elicit tau-P fall mainly or exclusively in the
physiological category, restraint is a prototypic emotional stres-
sor. Because established models of anxiety, fear, and social stress
share key features with restraint such as a capacity to engage a
stereotyped set of interconnected limbic forebrain cell groups
(Duncan et al., 1996; Campeau et al., 1997; Martinez et al., 2002),
the present findings suggest that the generality of stress-induced
tau-P may extend into the realm of stresses encountered in every-
day experience.
Several challenges that elicit tau-P are associated with marked
reductions in body temperature (7–10°C), which can differen-
tially modulate tau kinase and phosphatase activities, leading
Planel et al. (2001, 2004) to hypothesize that hypothermia may be
a common underlying mechanism. Restraint also results in re-
duced core temperature, although of lesser magnitude (0.5–2°C)
(Clement et al., 1989; Turek and Ryabinin, 2005; Meijer et al.,
2006). It remains to be determined whether the correlation be-
tween body temperature and tau-P noted in other paradigms
(Planel et al., 2007) extends to emotional stressors.
Whereas human tau is normally phosphorylated at 2–3 mol/
mol of protein, PHF-tau from AD brain is hyperphosphorylated
at a 7–10 molar ratio (Kopke et al., 1993). Murine tau can be
phosphorylated and form PHFs in vitro (Kampers et al., 1999).
We find that restraint provokes tau-P at each of seven epitopes
examined, all but one of whose responses is differentially modu-
lated by CRFR status. Coupled with the finding that central CRF
administration stimulates PHF-1 phosphorylation in a CRFR1-
dependent manner, we suggest a mechanism involving media-
Figure 5. CRFR1 antagonist blocks stress-induced tau-P. Quantitative Western blot analysis
oftau-PattheAT8andPHF-1sitesin hippocampal extracts from micepretreatedwithvehicle or
the small-molecule CRFR1 antagonist antalarmin and subjected to acute stress or no additional
treatment,expressedas a percentage of levels in untreated controls (C). At each site, antagonist
treatment did not affect basal levels of phosphorylation but blocked the stress-induced incre-
ment. The vehicle used for drug administration had no significant effect under basal or stress
conditions. **Differs significantly from unstressed controls ( p 0.001);
Differs from un
treated stressed group ( p 0.05). n 3 percondition.
-Actin was used as aloading control.
Rissman et al. CRF Receptors and Tau Phosphorylation J. Neurosci., June 13, 2007 27(24):6552– 6562 6557
tion by CRFR1, which is normally restrained by CRFR2-based
Signaling intermediates
Complementary monitoring of the activation status of tau ki-
nases identified several candidate effectors. GSK-3
has been im-
plicated in catalyzing tau-P at S
, and, to a lesser
extent, S
, and confers PHF-like changes (Liu et al., 2003).
Its activity is stimulated or inhibited by phosphorylation at Y
werealso stress responsive, and more so inCRFR2 knock-outs; these kinases were distinguished
by very high basal phosphorylation levels in CRFR1
mice, which may relate to elevated
tau-P observed in this condition at the AT8 site (see Fig. 3). Levels of phospho-ERKs, particularly
ERK1, were relatively unresponsive. Levels of cdk5 were stable across the conditions in force
here,butits p35 activator protein was strongly upregulated by stress inwt andCRFR2
Data are presented as mean SEM percentage of unstressed wt values. *Differs significantly
from wt control ( p 0.01); **p 0.001.
Differs significantly from wt stress condition ( p
-Actin was used as a loading control.
Figure 6. Modulation of tau kinase activity by stress and CRFR status. Western blot analyses
using phosphoepitope-specific antibodies to interrogate stress- and/or genotype-dependent
variations in the activation state of GSK-3, JNK46/54, and ERK1/2; relative levels of cdk5 and its
activator protein, p35, were also evaluated. The behavior of each kinase group recapitulates
aspects of the general pattern of tau-P responses in the same design. Thus, the activated
) form of GSK-3
is upregulated by stress in wt mice, and thisresponse is blocked CRFR1-
deficient animals and exaggerated in CRFR2 mutants. The inhibitory (pS
) form and total (un
phosphorylated) GSK3 are unresponsive over these conditions. Both phospho-JNK isoforms
Figure 7. Repeated stress results in chronic elevations and reduced solubility of phosphor-
ylated tau. Western analysis of hippocampal tau-P at the PHF-1 and AT8 sites of mice killed 20
min or 24 h after 30 min acute restraint or 14 consecutive daily exposures. Analysis was per-
formed on both soluble and detergent-soluble fractions. Under acute stress (AS) conditions,
tau-P is transient and contained wholly within the soluble fraction, whereas repeated stress
(RS) results in elevated levels of tau-P at both time points and the appearance of a significant
portion of phospho-tau in the detergent-soluble fraction. These data suggest that the effects of
repeatedemotional stress on tau-P are cumulative andassociatedwith increased sequestration
in the cellular fraction known to contain the bulk of PHFs in the AD brain. Note that for this
analysis, data are expressed as mean SEM optical density, rather than as a percentage of
controlvalues, to reflect thelackof detectable signal indetergent-solubleextracts under control
conditions. *Differs significantly from control ( p 0.01); **p 0.001.
-Actin was used as a
loading control. C, Control.
6558 J. Neurosci., June 13, 2007 27(24):6552– 6562 Rissman et al. CRF Receptors and Tau Phosphorylation
and S
, respectively (Cohen and Frame, 2001). We found stress-
induced increments in activated GSK-3
whose time course and
genotype dependence paralleled tau-P responses, without signif-
icant variation in the inhibitory form (cf. Okawa et al., 2003) or
total (unphosphorylated) GSK3 levels. The signaling intermedi-
ates that link CRFR ligand binding to alterations in GSK3 activity
are unclear. Though commonly associated with a Gs–cAMP–
protein kinase A mechanism, other signaling pathways can be
activated downstream of CRFRs by different G-proteins in a cell
type- and ligand-dependent manner (Grammatopoulos and
Chrousos, 2002; Arzt and Holsboer, 2006; Hillhouse and Gram-
matopoulos, 2006). Contributing to the lack of clarity is uncer-
tainty as to the proximate mechanism of tyrosine phosphoryla-
tion of GSK, with some reports identifying this as an
autophosphorylation event (Cole et al., 2004) and others impli-
cating distinct tyrosine kinases (Pyk2 and Fyn) in this regard (Lee
et al., 1998; Hartigan et al., 2001).
Similar stress- and genotype-dependent changes were ob-
served in levels of activated JNK, implicated in tau-P at the AT8
and PHF-1 epitopes (Atzori et al., 2001). High basal levels of
phospho-JNKs in CRFR1
mice paralleled, and may explain,
elevated AT8 and PHF-1 phosphorylation in this genotype. The
MAP kinases ERK1 and ERK2, which can target all tau sites ex-
amined here except T
(Drewes et al., 1992), were relatively
unresponsive. Relative levels of cdk5, a major tau kinase active at
, AT8, and PHF-1 sites (Patrick et al., 1999), were also stable
across conditions, but one of its activator proteins, p35, exhibited
strong CRFR-dependent stress responsiveness. Consistent with
previous findings (Okawa et al., 2003), we did not detect the
truncated p35 product, p25, which is a more potent cdk5 activa-
tor (Patrick et al., 1999).
Alterations in the activity of tau phosphatases, notably PP2A,
have also been implicated in stress-induced tau-P (Planel et al.,
2001, 2004). Here, we find that repeated
stress increases relative levels of the cata-
lytic subunit of PP2A, a finding that has
been associated with diminished enzy-
matic activity and potent autoregulation
(Baharians and Schonthal, 1998; Planel et
al., 2001). Our failure to discern an acute
stress effect on PP2A-c levels is not neces-
sarily indicative of a lack of phosphatase
involvement under these conditions.
Issues of interpretation
Two aspects of our findings warrant fur-
ther consideration. First, CRFR2
displayed exaggerated responses to stress
at five of seven phosphorylation sites and
in three activated kinases. Although these
data support an interaction with CRFR1
in regulating tau-P, whether they repre-
sent convergent or parallel effects is uncer-
tain. In preliminary studies, we find that
mice deficient in both CRFRs fail to man-
ifest acute restraint-induced tau-P, sup-
porting some degree of interdependence
(R. A. Rissman and P. E. Sawchenko, un-
published observations). This interpreta-
tion is consistent with evidence that CRF,
but not CRFR1 expression or binding, is
upregulated in brain regions of CRFR2-
deficient mice, and that CRFR1 antago-
nists can normalize aspects of the behavioral phenotype of these
mutants (Kishimoto et al., 2000; Bale and Vale, 2003). These
results suggest that exaggerated stress-induced tau-P of CRFR2
mutants does not result from alterations in CRFR1 expression or
distribution. Second, although the consistent lack of stress re-
sponsiveness of CRFR1
mice suggests a target for interven
tion in tau pathologies, this is offset by a tendency toward in-
creased basal tau-P (AT8 and PHF-1 sites) and activated kinase
(notably JNK) expression in CRFR1 mutants. In addition, the
need to supplement CRFR1-deficient mice with corticosterone
during the perinatal period complicates interpretation by expos-
ing animals to higher glucocorticoid levels during the stress-
hyporesponsive period (Baram et al., 1997) and the switch in the
dominant isoform of tau that occurs at this time (Kosik et al.,
1989). It is noteworthy in both respects that acute pharmacolog-
ical interference with CRFR1 blocked restraint-induced incre-
ments in tau-P without affecting basal levels, suggesting that the
elevated baselines seen in knock-outs may result from chronic
receptor deficiency.
CRF system involvement in AD
Exposure to stress can impact learning, memory, and hippocam-
pal morphology and function, and may confer increased risk of
AD (Wilson et al., 2003). Attention has focused on glucocorti-
coids as likely mediators of such effects, because increased circu-
lating levels of these hormones in aging have been linked to a
range of adverse effects in hippocampus (Sapolsky et al., 1985,
1986). Nevertheless, the present findings are consistent with
those of Korneyev et al. (1995) in demonstrating that stress-
induced tau-P proceeds unabated in animals lacking the capacity
to mount a glucocorticoid response, implicating instead the CRF
signaling system as integrally involved.
CRF is best known as a hypothalamic neuropeptide that gov-
Figure8. CRFRinvolvement in stress-inducedtauphosphorylation.Schematic summary of the progression of eventsleadingto
neurofibrillary tangle formation in AD, adapted with permission from Drewes (2004). Indicated on this are the present findings
supporting a differential involvement of CRFRs, acting via specific tau kinases, in mediating acute stress-induced tau-P (red
circles). Although acute stress effects are transient and readily reversible, repeated stress exposure produces cumulative increases
in phosphorylated tau, a portion of which is sequestered in detergent-soluble fractions. It remains to be determined whether
long-termincreases in stress exposureand/orsensitivity may result indevelopmentofthe paired helicalfilamentsandtangles that
represent a defining feature of AD neuropathology.
Rissman et al. CRF Receptors and Tau Phosphorylation J. Neurosci., June 13, 2007 27(24):6552– 6562 6559
erns the endocrine arm of the stress response (Vale et al., 1981).
Aspects of its central distribution and actions suggest a general
involvement in integrating hormonal, autonomic, and behav-
ioral adaptations (Chadwick et al., 1993), motivating consider-
ation of a role for this system in stress-induced tau-P. Alteration
in CRF immunoreactivity is a prominent neurochemical change
occurring early in AD progression (Davis et al., 1999), in brain
regions vulnerable to AD neuropathology (Powers et al., 1987;
Raadsheer et al., 1995; Pedersen et al., 2002; Rehman, 2002;
Swaab et al., 2005). It has been suggested that these changes result
from sequestration of peptide by a specific binding protein (CRF-
BP) (Behan et al., 1995), which can reversibly neutralize CRF
bioactivity. Accordingly, competitive antagonists of CRF-BP ac-
tion enhance performance on a range of learning and memory
tasks (Behan et al., 1995). In addition, marked increases in CRF
binding have been described in cortical areas of the AD brain (De
Souza et al., 1986). However, this work predated the cloning and
characterization of CRFRs, CRF-BP, and additional ligands that
interact differentially with them.
CRFR1-deficient mice exhibit impaired hormonal and behav-
ioral responses to stress, whereas CRFR2 knock-outs are hyper-
responsive on many of the same measures (Smith et al., 1998;
Timpl et al., 1998; Bale et al., 2000; Coste et al., 2000; Kishimoto
et al., 2000). Subsequent work indicates that CRFR interactions
are not necessarily starkly differential but has generally supported
convergent influences of the two receptor mechanisms on many
stress-related endpoints (Bale and Vale, 2004). The circuitry that
provides for their interaction the present context is unclear.
CRFR1 mRNA is expressed prominently in the pyramidal layer of
Ammon’s Horn and the hilus of the dentate gyrus, whereas
CRFR2 transcripts are weakly expressed throughout the principal
cell layers of both structures (Van Pett et al., 2000). Unfortu-
nately, the lack of validated antisera has precluded histochemical
characterization of receptor protein disposition. Regarding li-
gands, extrinsic CRF-containing inputs to hippocampus have not
been described, leaving local interneurons (Chen et al., 2004) and
the CSF (Arborelius et al., 1999) as possible sources for delivering
CRF to hippocampal CRFRs. Among the urocortins, only a
sparse urocortin 1-immunoreactive input to hippocampus has
been documented (Bittencourt and Sawchenko, 2000). The ap-
parent paucity of CRFR2 ligands in hippocampal afferents sug-
gests that their hypothesized interaction with CRFR1-dependent
mechanisms may occur outside the hippocampus.
Effects of repeated stress
Acute stress-induced tau-P has been consistently characterized as
a transient and reversible phenomenon. As such, it would seem
well positioned to contribute to the rapid dendritic/synaptic re-
modeling seen in the hippocampus in response to stress (Fuchs et
al., 2006), but its pathogenic relevance has remained uncertain
(see Fig. 8). The present finding that repeated stress exposure
results in sustained elevations in tau-P, a portion of which is
sequestered in a detergent-soluble form, supports such a poten-
tial, because the bulk of dispersed PHFs from the AD brain reside
in this same fraction (Iqbal et al., 1984; Rubenstein et al., 1986). It
remains to be determined whether protracted stress exposure can
lead to PHF/NFT pathology in animal models. We think it more
likely that stress-induced alterations in tau-P and solubility may
enhance the vulnerability of affected neurons to other experien-
tial or genetic factors that play on tau dynamics. This view is
coarsely analogous to the “endangerment” hypothesis to explain
the role of glucocorticoids in the age-related impairment of hip-
pocampal function (Sapolsky et al., 1985, 1986). Studies per-
formed over a lifespan, or in aging, will be required to fully ap-
preciate the contribution of stress exposure and/or sensitivity to
tau-related neuropathologies and the capacity of CRFR signaling
mechanisms to modulate them.
Alonso AC, Grundke-Iqbal I, Iqbal K (1996) Alzheimer’s disease hyper-
phosphorylated tau sequesters normal tau into tangles of filaments and
disassembles microtubules. Nat Med 2:783–787.
Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of
corticotropin-releasing factor in depression and anxiety disorders. J En-
docrinol 160:1–12.
Arendt T, Stieler J, Strijkstra AM, Hut RA, Rudiger J, Van der Zee EA, Har-
kany T, Holzer M, Hartig W (2003) Reversible paired helical filament-
like phosphorylation of tau is an adaptive process associated with neuro-
nal plasticity in hibernating animals. J Neurosci 23:6972– 6981.
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neuro-
fibrillary tangles but not senile plaques parallel duration and severity of
Alzheimer’s disease. Neurology 42:631– 639.
Arzt E, Holsboer F (2006) CRF signaling: molecular specificity for drug tar-
geting in the CNS. Trends Pharmacol Sci 27:531–538.
Atzori C, Ghetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB, Mirra SS,
Migheli A (2001) Activation of the JNK/p38 pathway occurs in diseases
characterized by tau protein pathology and is related to tau phosphoryla-
tion but not to apoptosis. J Neuropathol Exp Neurol 60:1190–1197.
Baharians Z, Schonthal AH (1998) Autoregulation of protein phosphatase
type 2A expression. J Biol Chem 273:19019 –19024.
Bale TL, Vale WW (2003) Increased depression-like behaviors in
corticotropin-releasing factor receptor-2-deficient mice: sexually dichot-
omous responses. J Neurosci 23:5295–5301.
Bale TL, Vale WW (2004) CRF and CRF receptors: role in stress responsivity
and other behaviors. Annu Rev Pharmacol Toxicol 44:525–557.
Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob
GF, Vale WW, Lee KF (2000) Mice deficient for corticotropin-releasing
hormone receptor-2 display anxiety-like behaviour and are hypersensi-
tive to stress. Nat Genet 24:410 414.
Baram TZ, Yi S, Avishai-Eliner S, Schultz L (1997) Development neurobi-
ology of the stress response: multilevel regulation of corticotropin-
releasing hormone function. Ann NY Acad Sci 814:252–265.
Bayatti N, Behl C (2005) The neuroprotective actions of corticotropin re-
leasing hormone. Ageing Res Rev 4:258 –270.
Behan DP, Heinrichs SC, Troncoso JC, Liu XJ, Kawas CH, Ling N, De Souza
EB (1995) Displacement of corticotropin releasing factor from its bind-
ing protein as a possible treatment for Alzheimer’s disease. Nature
Bittencourt JC, Sawchenko PE (2000) Do centrally administered neuropep-
tides access cognate receptors?: an analysis in the central corticotropin-
releasing factor system. J Neurosci 20:1142–1156.
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol (Berl) 82:239–259.
Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM
(1993) Abnormal tau phosphorylation at Ser396 in Alzheimer’s disease
recapitulates development and contributes to reduced microtubule bind-
ing. Neuron 10:1089–1099.
Campeau S, Falls WA, Cullinan WE, Helmreich DL, Davis M, Watson SJ
(1997) Elicitation and reduction of fear: behavioural and neuroendo-
crine indices and brain induction of the immediate-early gene c-fos. Neu-
roscience 78:1087–1104.
Chadwick D, Marsh J, Ackrill K (1993) Corticotropin-releasing factor.
Chichester, NY: Wiley.
Chen Y, Brunson KL, Adelmann G, Bender RA, Frotscher M, Baram TZ
(2004) Hippocampal corticotropin releasing hormone: pre- and
postsynaptic location and release by stress. Neuroscience 126:533–540.
Clement JG, Mills P, Brockway B (1989) Use of telemetry to record body
temperature and activity in mice. J Pharmacol Methods 21:129 –140.
Cohen P, Frame S (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol
Cole AR, Knebel A, Morrice NA, Robertson LA, Irving AJ, Connolly CN,
Sutherland C (2004) GSK-3 phosphorylation of the Alzheimer epitope
within collapsin response mediator proteins regulates axon elongation in
primary neurons. J Biol Chem 279:50176 –50180.
Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH,
6560 J. Neurosci., June 13, 2007 27(24):6552– 6562 Rissman et al. CRF Receptors and Tau Phosphorylation
Murray SE, Hill JK, Pantely GA, Hohimer AR, Hatton DC, Phillips TJ,
Finn DA, Low MJ, Rittenberg MB, Stenzel P, Stenzel-Poore MP (2000)
Abnormal adaptations to stress and impaired cardiovascular function in
mice lacking corticotropin-releasing hormone receptor-2. Nat Genet
Davis KL, Mohs RC, Marin DB, Purohit DP, Perl DP, Lantz M, Austin G,
Haroutunian V (1999) Neuropeptide abnormalities in patients with
early Alzheimer disease. Arch Gen Psychiatry 56:981–987.
Dayas CV, Buller KM, Crane JW, Xu Y, Day TA (2001) Stressor categoriza-
tion: acute physical and psychological stressors elicit distinctive recruit-
ment patterns in the amygdala and in medullary noradrenergic cell
groups. Eur J Neurosci 14:1143–1152.
De Souza EB, Whitehouse PJ, Kuhar MJ, Price DL, Vale WW (1986) Recip-
rocal changes in corticotropin-releasing factor (CRF)-like immunoreac-
tivity and CRF receptors in cerebral cortex of Alzheimer’s disease. Nature
Drewes G (2004) MARKing tau for tangles and toxicity. Trends Biochem Sci
Drewes G, Lichtenberg-Kraag B, Doring F, Mandelkow EM, Biernat J, Goris J,
Doree M, Mandelkow E (1992) Mitogen activated protein (MAP) ki-
nase transforms tau protein into an Alzheimer-like state. EMBO J
Duncan GE, Knapp DJ, Breese GR (1996) Neuroanatomical characteriza-
tion of Fos induction in rat behavioral models of anxiety. Brain Res
Feng Q, Cheng B, Yang R, Sun FY, Zhu CQ (2005) Dynamic changes of
phosphorylated tau in mouse hippocampus after cold water stress. Neu-
rosci Lett 388:13–16.
Fuchs E, Flugge G, Czeh B (2006) Remodeling of neuronal networks by
stress. Front Biosci 11:2746 –2758.
Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi
JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neuro-
fibrillary tangles in Alzheimer’s disease. Ann Neurol 41:17–24.
Grammatopoulos DK, Chrousos GP (2002) Functional characteristics of
CRH receptors and potential clinical applications of CRH-receptor an-
tagonists. Trends Endocrinol Metab 13:436 444.
Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM (2006)
Glucocorticoids increase amyloid-
and tau pathology in a mouse model
of Alzheimer’s disease. J Neurosci 26:9047–9056.
Gustke N, Steiner B, Mandelkow EM, Biernat J, Meyer HE, Goedert M, Man-
delkow E (1992) The Alzheimer-like phosphorylation of tau protein re-
duces microtubule binding and involves Ser-Pro and Thr-Pro motifs.
FEBS Lett 307:199–205.
Hartig W, Stieler J, Boerema AS, Wolf J, Schmidt U, Weissfuss J, Bullmann T,
Strijkstra AM, Arendt T (2007) Hibernation model of tau phosphoryla-
tion in hamsters: selective vulnerability of cholinergic basal forebrain
neurons—implications for Alzheimer’s disease. Eur J Neurosci 25:69 80.
Hartigan JA, Xiong WC, Johnson GV (2001) Glycogen synthase kinase
3beta is tyrosine phosphorylated by PYK2. Biochem Biophys Res Com-
mun 284:485– 489.
Herman JP, Cullinan WE (1997) Neurocircuitry of stress: central control of
the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci
20:78 84.
Higuchi M, Ishihara T, Zhang B, Hong M, Andreadis A, Trojanowski J, Lee
VM (2002) Transgenic mouse model of tauopathies with glial pathology
and nervous system degeneration. Neuron 35:433– 446.
Hillhouse EW, Grammatopoulos DK (2006) The molecular mechanisms
underlying the regulation of the biological activity of corticotropin-
releasing hormone receptors: implications for physiology and pathophys-
iology. Endocr Rev 27:260 –286.
Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-
Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lin-
coln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters
E, van Baren J, et al. (1998) Association of missense and 5-splice-site
mutations in tau with the inherited dementia FTDP-17. Nature
Ikeda Y, Ishiguro K, Fujita SC (2007) Ether stress-induced Alzheimer-like
tau phosphorylation in the normal mouse brain. FEBS Lett 581:891– 897.
Iqbal K, Zaidi T, Thompson CH, Merz PA, Wisniewski HM (1984) Alzhei-
mer paired helical filaments: bulk isolation, solubility, and protein com-
position. Acta Neuropathol (Berl) 62:167–177.
Iqbal K, Alonso AC, Gong CX, Khatoon S, Singh TJ, Grundke-Iqbal I (1994)
Mechanism of neurofibrillary degeneration in Alzheimer’s disease. Mol
Neurobiol 9:119 –123.
Jeong YH, Park CH, Yoo J, Shin KY, Ahn SM, Kim HS, Lee SH, Emson PC,
Suh YH (2006) Chronic stress accelerates learning and memory impair-
ments and increases amyloid deposition in APPV717I-CT100 transgenic
mice, an Alzheimer’s disease model. FASEB J 20:729 –731.
Kampers T, Pangalos M, Geerts H, Wiech H, Mandelkow E (1999) Assem-
bly of paired helical filaments from mouse tau: implications for the neu-
rofibrillary pathology in transgenic mouse models for Alzheimer’s dis-
ease. FEBS Lett 451:39 44.
Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F,
Hermanson O, Rosenfeld MG, Spiess J (2000) Deletion of crhr2 reveals
an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat
Genet 24:415– 419.
Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I (1993)
Microtubule-associated protein tau. Abnormal phosphorylation of a
non-paired helical filament pool in Alzheimer disease. J Biol Chem
Korneyev A, Binder L, Bernardis J (1995) Rapid reversible phosphorylation
of rat brain tau proteins in response to cold water stress. Neurosci Lett
Korneyev AY (1998) Stress-induced tau phosphorylation in mouse strains
with different brain Erk 1 2 immunoreactivity. Neurochem Res
Kosik KS, Orecchio LD, Bakalis S, Neve RL (1989) Developmentally regu-
lated expression of specific tau sequences. Neuron 2:1389–1397.
Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellen-
berg GD (2003) Neurodegeneration and defective neurotransmission in
a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci USA
Lee SC, Kuan CY, Wen ZD, Yang SD (1998) The naturally occurring PKC
inhibitor sphingosine and tumor promoter phorbol ester potentially in-
duce tyrosine phosphorylation/activation of oncogenic proline-directed
protein kinase FA/GSK-3alpha in a common signalling pathway. J Protein
Chem 17:15–27.
Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, Netzer WJ, Xu H, Wang JZ
(2003) Overactivation of glycogen synthase kinase-3 by inhibition of
phosphoinositol-3 kinase and protein kinase C leads to hyperphosphory-
lation of tau and impairment of spatial memory. J Neurochem
Martinez M, Calvo-Torrent A, Herbert J (2002) Mapping brain response to
social stress in rodents with c-fos expression: a review. Stress 5:3–13.
Meijer MK, Spruijt BM, van Zutphen LF, Baumans V (2006) Effect of re-
straint and injection methods on heart rate and body temperature in
mice. Lab Anim 40:382–391.
Okawa Y, Ishiguro K, Fujita SC (2003) Stress-induced hyperphosphoryla-
tion of tau in the mouse brain. FEBS Lett 535:183–189.
Papasozomenos SC (1996) Heat shock induces rapid dephosphorylation of
tau in both female and male rats followed by hyperphosphorylation only
in female rats: implications for Alzheimer’s disease. J Neurochem
Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999)
Conversion of p35 to p25 deregulates Cdk5 activity and promotes neuro-
degeneration. Nature 402:615–622.
Pedersen WA, Wan R, Zhang P, Mattson MP (2002) Urocortin, but not
urocortin II, protects cultured hippocampal neurons from oxidative and
excitotoxic cell death via corticotropin-releasing hormone receptor type
I. J Neurosci 22:404 412.
Pernar L, Curtis AL, Vale WW, Rivier JE, Valentino RJ (2004) Selective
activation of corticotropin-releasing factor-2 receptors on neurochemi-
cally identified neurons in the rat dorsal raphe nucleus reveals dual ac-
tions. J Neurosci 24:1305–1311.
Planel E, Yasutake K, Fujita SC, Ishiguro K (2001) Inhibition of protein
phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3
beta and cyclin-dependent kinase 5 inhibition and results in tau hyper-
phosphorylation in the hippocampus of starved mouse. J Biol Chem
Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, Murayama O,
Ishiguro K, Tatebayashi Y, Takashima A (2004) Alterations in glucose
metabolism induce hypothermia leading to tau hyperphosphorylation
through differential inhibition of kinase and phosphatase activities: im-
plications for Alzheimer’s disease. J Neurosci 24:2401–2411.
Rissman et al. CRF Receptors and Tau Phosphorylation J. Neurosci., June 13, 2007
27(24):6552–6562 6561
Planel E, Richter KE, Nolan CE, Finley JE, Liu L, Wen Y, Krishnamurthy P,
Herman M, Wang L, Schachter JB, Nelson RB, Lau LF, Duff KE (2007)
Anesthesia leads to tau hyperphosphorylation through inhibition of
phosphatase activity by hypothermia. J Neurosci 27:3090 –3097.
Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, An-
dreadis A, Wiederholt WC, Raskind M, Schellenberg GD (1998) Tau is a
candidate gene for chromosome 17 frontotemporal dementia. Ann Neu-
rol 43:815– 825.
Powers RE, Walker LC, DeSouza EB, Vale WW, Struble RG, Whitehouse PJ,
Price DL (1987) Immunohistochemical study of neurons containing
corticotropin-releasing factor in Alzheimer’s disease. Synapse 1:405–410.
Raadsheer FC, van Heerikhuize JJ, Lucassen PJ, Hoogendijk WJ, Tilders FJ,
Swaab DF (1995) Corticotropin-releasing hormone mRNA levels in the
paraventricular nucleus of patients with Alzheimer’s disease and depres-
sion. Am J Psychiatry 152:1372–1376.
Rehman HU (2002) Role of CRH in the pathogenesis of dementia of Alz-
heimer’s type and other dementias. Curr Opin Investig Drugs
Rubenstein R, Kascsak RJ, Merz PA, Wisniewski HM, Carp RI, Iqbal K
(1986) Paired helical filaments associated with Alzheimer disease are
readily soluble structures. Brain Res 372:80 88.
Sapolsky RM, Krey LC, McEwen BS (1985) Prolonged glucocorticoid expo-
sure reduces hippocampal neuron number: implications for aging. J Neu-
rosci 5:1222–1227.
Sapolsky RM, Krey LC, McEwen BS (1986) The neuroendocrinology of
stress and aging: the glucocorticoid cascade hypothesis. Endocr Rev
Sawchenko PE, Brown ER, Chan RK, Ericsson A, Li HY, Roland BL, Kovacs KJ
(1996) The paraventricular nucleus of the hypothalamus and the func-
tional neuroanatomy of visceromotor responses to stress. Prog Brain Res
Sawchenko PE, Li HY, Ericsson A (2000) Circuits and mechanisms govern-
ing hypothalamic responses to stress: a tale of two paradigms. Prog Brain
Res 122:61–78.
Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K (1998)
Phosphorylation of tau at both Thr 231 and Ser 262 is required for max-
imal inhibition of its binding to microtubules. Arch Biochem Biophys
Shu SY, Penny GR, Peterson GM (1988) The ‘marginal division’: a new
subdivision in the neostriatum of the rat. J Chem Neuroanat 1:147–163.
Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen
R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W,
Lee KF (1998) Corticotropin releasing factor receptor 1-deficient mice
display decreased anxiety, impaired stress response, and aberrant neu-
roendocrine development. Neuron 20:1093–1102.
Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B (1998)
Mutation in the tau gene in familial multiple system tauopathy with pre-
senile dementia. Proc Natl Acad Sci USA 95:7737–7741.
Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM (2002) Tau
blocks traffic of organelles, neurofilaments, and APP vesicles in neurons
and enhances oxidative stress. J Cell Biol 156:1051–1063.
Swaab DF, Bao AM, Lucassen PJ (2005) The stress system in the human
brain in depression and neurodegeneration. Ageing Res Rev 4:141–194.
Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V,
Steckler T, Holsboer F, Wurst W (1998) Impaired stress response and
reduced anxiety in mice lacking a functional corticotropin-releasing hor-
mone receptor 1. Nat Genet 19:162–166.
Turek VF, Ryabinin AE (2005) Expression of c-Fos in the mouse Edinger-
Westphal nucleus following ethanol administration is not secondary to
hypothermia or stress. Brain Res 1063:132–139.
Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue
ovine hypothalamic peptide that stimulates secretion of corticotropin and
beta-endorphin. Science 213:1394–1397.
Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, Prins GS, Perrin
M, Vale W, Sawchenko PE (2000) Distribution of mRNAs encoding
CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol
Watts AG (1996) The impact of physiological stimuli on the expression of
corticotropin-releasing hormone (CRH) and other neuropeptide genes.
Front Neuroendocrinol 17:281–326.
Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC, Chrousos GP
(1996) In vivo and in vitro characterization of antalarmin, a nonpeptide
corticotropin-releasing hormone (CRH) receptor antagonist: suppres-
sion of pituitary ACTH release and peripheral inflammation. Endocrinol-
ogy 137:5747–5750.
Wilson RS, Evans DA, Bienias JL, Mendes de Leon CF, Schneider JA, Bennett
DA (2003) Proneness to psychological distress is associated with risk of
Alzheimer’s disease. Neurology 61:1479 –1485.
Yanagisawa M, Planel E, Ishiguro K, Fujita SC (1999) Starvation induces tau
hyperphosphorylation in mouse brain: implications for Alzheimer’s dis-
ease. FEBS Lett 461:329 –333.
Yoshida S, Maeda M, Kaku S, Ikeya H, Yamada K, Nakaike S (2006) Lithium
inhibits stress-induced changes in tau phosphorylation in the mouse hip-
pocampus. J Neural Transm 113:1803–1814.
6562 J. Neurosci., June 13, 2007 27(24):6552– 6562 Rissman et al. CRF Receptors and Tau Phosphorylation
    • "Our study demonstrates that CRF induces tau-P in a manner consistent with our in vivo stud- ies565758. In these in vivo studies, we found that chronic stress or CRF overexpression caused sequestration of tau aggregates into detergent-soluble cellular fractions [56, 57] . "
    [Show abstract] [Hide abstract] ABSTRACT: Stress exposure or increased levels of corticotropin-releasing factor (CRF) induce hippocampal tau phosphorylation (tau-P) in rodent models, a process that is dependent on the type-1 CRF receptor (CRFR1). Although these preclinical studies on stress-induced tau-P provide mechanistic insight for epidemiological work that identifies stress as a risk factor for Alzheimer's disease (AD), the actual impact of stress-induced tau-P on neuronal function remains unclear. To determine the functional consequences of stress-induced tau-P, we developed a novel mouse neuronal cell culture system to explore the impact of acute (0.5hr) and chronic (2hr) CRF treatment on tau-P and integral cell processes such as axon transport. Consistent with in vivo reports, we found that chronic CRF treatment increased tau-P levels and caused globular accumulations of phosphorylated tau in dendritic and axonal processes. Furthermore, while both acute and chronic CRF treatment led to significant reduction in CREB activation and axon transport of brain-derived neurotrophic factor (BDNF), this was not the case with mitochondrial transport. Acute CRF treatment caused increased mitochondrial velocity and distance traveled in neurons, while chronic CRF treatment modestly decreased mitochondrial velocity and greatly increased distance traveled. These results suggest that transport of cellular energetics may take priority over growth factors during stress. Tau-P was required for these changes, as co-treatment of CRF with a GSK kinase inhibitor prevented CRF-induced tau-P and all axon transport changes. Collectively, our results provide mechanistic insight into the consequences of stress peptide-induced tau-P and provide an explanation for how chronic stress via CRF may lead to neuronal vulnerability in AD.
    Full-text · Article · Jan 2016
    • "It has also been implicated in AD. The effects of stress on b-amyloid and p-tau were prevented by blocking the CRF type 1 receptor (Carroll et al., 2011; Rissman et al., 2012 Rissman et al., , 2007 Justice et al., 2015), suggesting that CRF as well as GCs may contribute to the potentiation of AD (Joshi et al., 2012; Kang et al., 2007). It is important to remember that CRF has actions in the brain outside the HPA axis and that all the actions of the HPA axis may not be due solely to corticoids. "
    [Show abstract] [Hide abstract] ABSTRACT: Depression (MDD) is prodromal to, and a component of, Alzheimer’s disease (AD): it may also be a trigger for incipient AD. MDD is not a unitary disorder, so there may be particular subtypes of early life MDD that pose independent high risks for later AD, though the identification of these subtypes is problematical. There may either be a common pathological event underlying both MDD and AD, or MDD may sensitize the brain to a second event (‘hit’) that precipitates AD. MDD may also accelerate brain ageing, including altered DNA methylation, increased cortisol but decreasing DHEA and thus the risk for AD. So far, genes predicting AD (e.g. APOEε4) are not risk factors for MDD, and those implicated in MDD (e.g. SLC6A4) are not risks for AD, so a common genetic predisposition looks unlikely. There is as yet no strong indication that an epigenetic event occurs during some forms of MDD that predisposes to later AD, though the evidence is limited.
    Full-text · Article · Dec 2015
    • "All rights reserved. phospho-tau levels returned to baseline level after 90 min of acute restrain stress (Rissman et al. 2007). Overall, our study suggests that increasing of Aβ-oligomers levels stimulated by modern life-like stress might impact the synaptic plasticity and induce a robust synaptic loss in the 3xTg-AD mice. "
    [Show abstract] [Hide abstract] ABSTRACT: Alzheimer's disease (AD) is a progressive neurological disorder that impairs memory and other cognitive functions in the elderly. The social and financial impacts of AD are overwhelming and are escalating exponentially as a result of population aging. Therefore, identifying AD-related risk factors and the development of more efficacious therapeutic approaches are critical to cure this neurological disorder. Current epidemiological evidence indicates that life experiences, including chronic stress, are a risk for AD. However, it is unknown if short-term stress, lasting for hours, influences the onset or progression of AD. Here, we determined the effect of short-term, multi-modal 'modern life-like' stress on AD pathogenesis and synaptic plasticity in mice bearing three AD mutations (the 3xTg-AD mouse model). We found that combined emotional and physical stress lasting 5 hours severely impaired memory in wild-type mice and tended to impact it in already low-performing 3xTg-AD mice. This stress reduced the number of synapse-bearing dendritic spines in 3xTg-AD mice and increased Aβ levels by augmenting AβPP processing. Thus, short-term stress simulating modern-life conditions may exacerbate cognitive deficits in preclinical AD by accelerating amyloid pathology and reducing synapse numbers. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Full-text · Article · Jun 2015
Show more